



Clinical trial results:

A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (AntiPD1 Antibody) Compared with Docetaxel in Patients with NonSmall Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen

Summary

EudraCT number	2018-000245-39
Trial protocol	SK LT BG PL
Global end of trial date	18 January 2024

Results information

Result version number	v1 (current)
This version publication date	01 February 2025
First version publication date	01 February 2025

Trial information

Trial identification

Sponsor protocol code	BGB-A317-303
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03358875
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	BeiGene
Sponsor organisation address	1840 Gateway Drive, San Mateo, United States, 94404
Public contact	BeiGene USA, Inc., BeiGene Clinical Support, 1 877-828-5568, clinicaltrials@beigene.com
Scientific contact	BeiGene USA, Inc., BeiGene Clinical Support, 1 877-828-5568, clinicaltrials@beigene.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 January 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	18 January 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To compare the efficacy, as measured by overall survival (OS), of tislelizumab with docetaxel in the second- or third-line setting in patients with non-small cell lung cancer (NSCLC) who have progressed on a prior platinum-containing regimen. A comparison of the treatment arms will be performed in:

- o The intent-to-treat (ITT) analysis set
- o The program cell death protein ligand-1 (PD-L1) positive analysis set, where PD-L1 positive is defined as $\geq 25\%$ of tumor cells (TCs) with PD-L1 membrane staining via the Ventana SP263 assay.

Protection of trial subjects:

This study was conducted in accordance with BeiGene procedures, which comply with the principles of Good Clinical Practice (GCP), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, the Declaration of Helsinki, and local regulatory requirements.

The protocol, any amendments, and informed consent forms (ICFs) were reviewed and approved by the Independent Ethics Committees (IEC)/Institutional Review Board (IRB) in conformance with GCP and applicable regulatory requirements.

The IEC/IRB-approved ICF was signed and dated by the patient or the patient's legally authorized representative before his or her participation in the study. A copy of each signed ICF was provided to the patient or the patient's legally authorized representative.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 November 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Brazil: 25
Country: Number of subjects enrolled	China: 641
Country: Number of subjects enrolled	Mexico: 14
Country: Number of subjects enrolled	New Zealand: 14
Country: Number of subjects enrolled	Russian Federation: 56
Country: Number of subjects enrolled	Türkiye: 39
Country: Number of subjects enrolled	Poland: 4
Country: Number of subjects enrolled	Slovakia: 5
Country: Number of subjects enrolled	Bulgaria: 2
Country: Number of subjects enrolled	Lithuania: 5
Worldwide total number of subjects	805
EEA total number of subjects	16

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	523
From 65 to 84 years	281
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

This study was conducted at 109 study centers in 10 countries (China, Brazil, Bulgaria, Lithuania, Mexico, New Zealand, Poland, Russia, Slovakia, and Turkey).

Pre-assignment

Screening details:

Eligible participants were randomized in a 2:1 ratio to receive either tislelizumab or docetaxel treatment. Randomization was stratified by histology (squamous versus non--squamous), line of therapy (second line versus third line), and programmed cell death protein ligand-1 (PD-L1) expression ($\geq 25\%$ tumor cells (TCs) versus $< 25\%$ TCs).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Tislelizumab
------------------	--------------

Arm description:

Participants received tislelizumab 200 mg intravenously (IV) once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.

Arm type	Experimental
Investigational medicinal product name	Tislelizumab
Investigational medicinal product code	BGB-A317
Other name	TEVIMBRA®
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Tislelizumab 200 mg administered intravenously once every 3 weeks.

Arm title	Docetaxel
------------------	-----------

Arm description:

Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.

Arm type	Active comparator
Investigational medicinal product name	Docetaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Docetaxel 75 mg/m² administered intravenously once every 3 weeks

Number of subjects in period 1	Tislelizumab	Docetaxel
Started	535	270
Received Treatment	534	258
Completed	0	0
Not completed	535	270
Study Closed by Sponsor	66	29
Consent withdrawn by subject	13	16
Death	409	223
Remained on Study	1	-
Miscellaneous	33	-
Lost to follow-up	13	2

Baseline characteristics

Reporting groups

Reporting group title	Tislelizumab
-----------------------	--------------

Reporting group description:

Participants received tislelizumab 200 mg intravenously (IV) once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.

Reporting group title	Docetaxel
-----------------------	-----------

Reporting group description:

Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.

Reporting group values	Tislelizumab	Docetaxel	Total
Number of subjects	535	270	805
Age categorical			
Units: Subjects			
< 65 years	351	172	523
≥ 65 - < 75 years	167	86	253
≥ 75 - < 85 years	16	12	28
≥ 85 years	1	0	1
Age continuous			
Units: years			
arithmetic mean	60.4	60.27	-
standard deviation	± 8.879	± 8.95	-
Gender categorical			
Units: Subjects			
Female	119	64	183
Male	416	206	622
Race			
Units: Subjects			
American Indian or Alaska Native	12	1	13
Asian	424	219	643
Black or African American	1	3	4
Native Hawaiian or Other Pacific Islander	3	3	6
White	93	44	137
Other	2	0	2
Histology			
Units: Subjects			
Squamous	248	122	370
Non-Squamous	287	148	435
Current Line of Therapy			
Units: Subjects			
Second	453	229	682
Third	82	41	123
PD-L1 Expression			
Participants were tested for PD-L1 expression by a central laboratory using VENTANA SP263 immunohistochemistry assay.			
Units: Subjects			
≥ 25% of tumor cells	227	115	342

< 25% of tumor cells	307	152	459
Missing	1	3	4
Smoking Status			
Units: Subjects			
Never	162	82	244
Current	50	20	70
Former	323	168	491

End points

End points reporting groups

Reporting group title	Tislelizumab
Reporting group description:	Participants received tislelizumab 200 mg intravenously (IV) once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.
Reporting group title	Docetaxel
Reporting group description:	Participants received docetaxel 75 mg/m ² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.

Primary: Overall Survival (OS) in All Participants (Co-primary Endpoint)

End point title	Overall Survival (OS) in All Participants (Co-primary Endpoint)
End point description:	OS was defined as the time from randomization to death from any cause. Median OS was calculated using the Kaplan-Meier method. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Data for participants who did not have postbaseline information were censored at the date of randomization. The Intent-to-Treat (ITT) Analysis Set included all randomized patients.
End point type	Primary
End point timeframe:	From randomization to the data cutoff date of 10 August 2020; up to 32.4 months

End point values	Tislelizumab	Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	535	270		
Units: months				
median (confidence interval 95%)	17.2 (15.28 to 20.04)	11.9 (10.18 to 13.93)		

Statistical analyses

Statistical analysis title	Analysis of OS in All Participants
Comparison groups	Tislelizumab v Docetaxel
Number of subjects included in analysis	805
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[1]
Method	1-sided Log Rank Test
Parameter estimate	Hazard ratio (HR)
Point estimate	0.64

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.527
upper limit	0.778

Notes:

[1] - OS in the ITT population was tested at one-sided p value boundary of 0.0120.

One-sided log rank test stratified by stratification factors: histology (squamous vs non-squamous), line of therapy (second vs third), and PDL1 expression ($\geq 25\%$ vs $< 25\%$ TC)

Primary: Overall Survival (OS) in Programmed Cell Death Protein Ligand-1 (PD-L1)-Positive Participants (Co-primary Endpoint)

End point title	Overall Survival (OS) in Programmed Cell Death Protein Ligand-1 (PD-L1)-Positive Participants (Co-primary Endpoint)
-----------------	---

End point description:

OS was defined as the time from randomization to death from any cause. Median OS was calculated using the Kaplan-Meier method. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Data for participants who did not have postbaseline information were censored at the date of randomization.

The PD-L1-Positive Analysis Set included all randomized patients whose tumors were PD-L1 positive (defined as $\geq 25\%$ of tumor cells with PD-L1 membrane staining).

End point type	Primary
----------------	---------

End point timeframe:

From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months

End point values	Tislelizumab	Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	227 ^[2]	115 ^[3]		
Units: months				
median (confidence interval 95%)	19.3 (16.49 to 22.60)	11.5 (8.15 to 13.54)		

Notes:

[2] - The PD-L1-Positive Analysis Set

[3] - The PD-L1-Positive Analysis Set

Statistical analyses

Statistical analysis title	Analysis of OS in PD-L1-Positive Participants
Comparison groups	Tislelizumab v Docetaxel
Number of subjects included in analysis	342
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[4]
Method	1-sided Log Rank Test
Parameter estimate	Hazard ratio (HR)
Point estimate	0.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.407
upper limit	0.702

Notes:

[4] - OS in the PD-L1 positive analysis set was tested at the one-sided p-value boundary of 0.025. One-sided log rank test stratified by stratification factors: histology (squamous vs non-squamous) and line of therapy (second vs third).

Secondary: Objective Response Rate (ORR) in All Participants

End point title	Objective Response Rate (ORR) in All Participants
-----------------	---

End point description:

Objective response rate is defined as the percentage of participants who had a complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments included computed tomography (CT) scans or magnetic resonance imaging (MRI), with preference for CT, of the chest, abdomen, and pelvis.

CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

PR: At least a 30% decrease in the size of target lesions and no progression of non-target lesions and no new lesions, or disappearance of all target lesions with persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits and no new lesions.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months

End point values	Tislelizumab	Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	535	270		
Units: percentage of participants				
number (confidence interval 95%)	22.6 (19.14 to 26.40)	7.0 (4.29 to 10.77)		

Statistical analyses

Statistical analysis title	Analysis of ORR in All Participants
Comparison groups	Tislelizumab v Docetaxel
Number of subjects included in analysis	805
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [5]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	3.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.336
upper limit	6.393

Notes:

[5] - Cochran-Mantel-Haenszel (CMH) chi-square test stratified by histology, line of therapy, and PDL1 expression.

Secondary: Objective Response Rate in PD-L1-Positive Participants

End point title	Objective Response Rate in PD-L1-Positive Participants
-----------------	--

End point description:

Objective response rate is defined as the percentage of participants who had a complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments included computed tomography (CT) scans or magnetic resonance imaging (MRI), with preference for CT, of the chest, abdomen, and pelvis.

CR: Disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

PR: At least a 30% decrease in the size of target lesions and no progression of non-target lesions and no new lesions, or disappearance of all target lesions with persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits and no new lesions.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months

End point values	Tislelizumab	Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	227 ^[6]	115 ^[7]		
Units: percentage of participants				
number (confidence interval 95%)	37.4 (31.13 to 44.09)	7.0 (3.05 to 13.25)		

Notes:

[6] - PD-L1-Positive Analysis Set

[7] - PD-L1-Positive Analysis Set

Statistical analyses

Statistical analysis title	Analysis of ORR in PD-L1-Positive Participants
Comparison groups	Tislelizumab v Docetaxel
Number of subjects included in analysis	342
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[8]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	8.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.721
upper limit	17.379

Notes:

[8] - Cochran-Mantel-Haenszel (CMH) chi-square test stratified by histology and line of therapy.

Secondary: Duration of Response (DOR) for All Responders

End point title	Duration of Response (DOR) for All Responders
-----------------	---

End point description:

DOR was defined as the time from the first documented objective response to documented disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first.

Median DOR was estimated using the Kaplan-Meier method.

Progressive Disease (PD): At least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions, or the appearance of any

new lesions.

End point type	Secondary
End point timeframe:	
From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months	

End point values	Tislelizumab	Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	121 ^[9]	19 ^[10]		
Units: months				
median (confidence interval 95%)	13.5 (8.54 to 19.58)	6.0 (2.10 to 7.16)		

Notes:

[9] - Participants in the Intent-to-Treat Analysis Set who had an objective response

[10] - Participants in the Intent-to-Treat Analysis Set who had an objective response

Statistical analyses

Statistical analysis title	Analysis of DOR in All Responders
Comparison groups	Tislelizumab v Docetaxel
Number of subjects included in analysis	140
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[11]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.176
upper limit	0.536

Notes:

[11] - Stratified by stratification factors: histology (squamous vs non-squamous), line of therapy (second vs third), and PDL1 expression ($\geq 25\%$ vs $< 25\%$ TC).

Secondary: Duration of Response (DOR) in PD-L1-Positive Responders

End point title	Duration of Response (DOR) in PD-L1-Positive Responders
End point description:	
DOR was defined as the time from the first documented objective response to documented disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first.	
Median DOR was estimated using the Kaplan-Meier method.	
Progressive Disease (PD): At least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions, or the appearance of any new lesions.	
End point type	Secondary
End point timeframe:	
From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months	

End point values	Tislelizumab	Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	85 ^[12]	8 ^[13]		
Units: months				
median (confidence interval 95%)	11.9 (8.31 to 19.58)	4.2 (0.56 to 6.05)		

Notes:

[12] - Participants in the PD-L1-Positive Analysis Set who had an objective response

[13] - Participants in the PD-L1-Positive Analysis Set who had an objective response

Statistical analyses

Statistical analysis title	Analysis of DOR in PD-L1-Positive Responders
Comparison groups	Tislelizumab v Docetaxel
Number of subjects included in analysis	93
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[14]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.066
upper limit	0.37

Notes:

[14] - Stratified by stratification factors: histology (squamous vs non-squamous) and line of therapy (second vs third).

Secondary: Progression-free Survival (PFS) in All Participants

End point title	Progression-free Survival (PFS) in All Participants
End point description:	PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
End point type	Secondary
End point timeframe:	From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months

End point values	Tislelizumab	Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	535	270		
Units: months				
median (confidence interval 95%)	4.2 (3.88 to 5.52)	2.6 (2.17 to 3.78)		

Statistical analyses

Statistical analysis title	Analysis of PFS in All Participants
Comparison groups	Tislelizumab v Docetaxel
Number of subjects included in analysis	805
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [15]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.63
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.528
upper limit	0.745

Notes:

[15] - Stratified by stratification factors: histology (squamous vs non-squamous), line of therapy (second vs third), and PDL1 expression ($\geq 25\%$ vs $< 25\%$ TC).

Secondary: Progression-free Survival in PD-L1 Positive Participants

End point title	Progression-free Survival in PD-L1 Positive Participants
-----------------	--

End point description:

PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months

End point values	Tislelizumab	Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	227 ^[16]	115 ^[17]		
Units: months				
median (confidence interval 95%)	6.5 (6.24 to 8.28)	2.5 (2.10 to 4.11)		

Notes:

[16] - PD-L1 Positive Analysis Set

[17] - PD-L1 Positive Analysis Set

Statistical analyses

Statistical analysis title	Analysis of PFS in PD-L1-Positive Participants
Comparison groups	Tislelizumab v Docetaxel
Number of subjects included in analysis	342
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [18]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.285
upper limit	0.494

Notes:

[18] - Stratified by stratification factors: histology (squamous vs non-squamous) and line of therapy (second vs third).

Secondary: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) Score

End point title	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) Score
-----------------	---

End point description:

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and two global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS/QoL score indicates better quality of life.

The health-related quality of life (HRQoL) Analysis Set included all randomized participants who received ≥ 1 dose of study drug and completed ≥ 1 HRQoL assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Cycle 6 (each cycle was 3 weeks)

End point values	Tislelizumab	Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	316 ^[19]	76 ^[20]		
Units: score on a scale				
least squares mean (confidence interval 95%)	2.4 (0.62 to 4.12)	-3.4 (-6.45 to -0.27)		

Notes:

[19] - Participants in the HRQoL Analysis set with available data at Baseline and Cycle 6

[20] - Participants in the HRQoL Analysis set with available data at Baseline and Cycle 6

Statistical analyses

Statistical analysis title	Analysis of EORTC QLQ-C30 GHS/QoL Score
Comparison groups	Tislelizumab v Docetaxel
Number of subjects included in analysis	392
Analysis specification	Pre-specified
Analysis type	other ^[21]
P-value	= 0.0008
Method	Mixed models analysis
Parameter estimate	Least Squares (LS) Mean Difference
Point estimate	5.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.38
upper limit	9.07

Notes:

[21] - The linear mixed-effect model for repeated measures (MMRM) includes baseline score, stratification factors, treatment arm, visit, and treatment arm by visit interaction as fixed effects and visit as a repeated measure.

Secondary: Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 Items (QLQ-LC13) Coughing, Dyspnoea, and Chest Pain Scores

End point title	Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 Items (QLQ-LC13) Coughing, Dyspnoea, and Chest Pain Scores
-----------------	---

End point description:

The EORTC QLQ-LC13 is the lung cancer module of the QLQ-C30 and measures lung cancer-specific disease and treatment symptoms. It includes 13 questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. Lower scores indicate an improvement in symptoms.

The HRQoL Analysis Set included all randomized participants who received ≥ 1 dose of study drug and completed ≥ 1 HRQoL assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Cycle 6 (each cycle was 3 weeks)

End point values	Tislelizumab	Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	316 ^[22]	77 ^[23]		
Units: score on a scale				
least squares mean (confidence interval 95%)				
Coughing Scale	-7.8 (-10.23 to -5.30)	0.5 (-3.87 to 4.87)		
Dyspnoea Scale	-1.2 (-2.93 to 0.56)	2.0 (-1.01 to 5.05)		
Chest Pain Scale	-0.9 (-2.86 to 1.06)	1.3 (-2.15 to 4.84)		

Notes:

[22] - Participants in the HRQoL Analysis Set with available data at Baseline and Cycle 6

[23] - Participants in the HRQoL Analysis Set with available data at Baseline and Cycle 6

Statistical analyses

Statistical analysis title	Analysis of EORTC QLQ-LC13 Coughing Scale
Statistical analysis description: The linear mixed-effect model for repeated measures (MMRM) includes baseline score, stratification factors, treatment arm, visit, and treatment arm by visit interaction as fixed effects and visit as a repeated measure.	
Comparison groups	Tislelizumab v Docetaxel
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0007
Method	Mixed models analysis
Parameter estimate	LS Mean Difference
Point estimate	-8.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.02
upper limit	-3.51

Statistical analysis title	Analysis of EORTC QLQ-LC13 Dyspnoea Scale
Statistical analysis description: The linear mixed-effect model for repeated measures (MMRM) includes baseline score, stratification factors, treatment arm, visit, and treatment arm by visit interaction as fixed effects and visit as a repeated measure.	
Comparison groups	Tislelizumab v Docetaxel
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.0579
Method	Mixed models analysis
Parameter estimate	LS Mean Difference
Point estimate	-3.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.52
upper limit	0.11

Statistical analysis title	Analysis of EORTC QLQ-LC13 Chest Pain Scale
Statistical analysis description: The linear mixed-effect model for repeated measures (MMRM) includes baseline score, stratification factors, treatment arm, visit, and treatment arm by visit interaction as fixed effects and visit as a repeated measure.	
Comparison groups	Tislelizumab v Docetaxel

Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.2472
Method	Mixed models analysis
Parameter estimate	LS Mean Difference
Point estimate	-2.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.05
upper limit	1.56

Secondary: Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)

End point title	Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS)
End point description: The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.	
End point type	Secondary
End point timeframe: Baseline and Cycle 6 (each cycle was 3 weeks)	

End point values	Tislelizumab	Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	237 ^[24]	60 ^[25]		
Units: score on a scale				
arithmetic mean (standard deviation)	1.0 (± 11.89)	1.7 (± 11.36)		

Notes:

[24] - Participants in the HRQoL Analysis Set with available data at Baseline and Cycle 6

[25] - Participants in the HRQoL Analysis Set with available data at Baseline and Cycle 6

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

End point title	Number of Participants With Treatment-emergent Adverse Events (TEAEs)
End point description: The investigator assessed the severity of each AE and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03 as defined below: -Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. -Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate activities of daily living.	

-Grade 3: Severe or medically significant but not immediately life threatening. hospitalization or prolongation of hospitalization indicated; disabling; limiting selfcare activities of daily living.

-Grade 4: Life threatening consequences; urgent intervention indicated.

-Grade 5: Death related to AE.

The Safety Analysis Set included all randomized patients who received ≥ 1 dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug to 30 days after last dose, up to the study completion date cut-off date of 18 January 2024 (up to approximately 63 months)

End point values	Tislelizumab	Docetaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	534 ^[26]	258 ^[27]		
Units: participants				
Any TEAE	518	254		
\geq Grade 3 TEAE	233	193		

Notes:

[26] - Safety Analysis Set

[27] - Safety Analysis Set

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of study treatment until 30 days after the last dose, up to study completion date cut-off date of 18 January 2024, up to 63 months.

Adverse event reporting additional description:

Deaths, serious adverse events, and non-serious adverse events are reported for all randomized participants who received ≥ 1 dose of any study treatment.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24
--------------------	----

Reporting groups

Reporting group title	Docetaxel
-----------------------	-----------

Reporting group description:

Participants received docetaxel 75 mg/m² IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.

Reporting group title	Tislelizumab
-----------------------	--------------

Reporting group description:

Participants received tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.

Serious adverse events	Docetaxel	Tislelizumab	
Total subjects affected by serious adverse events			
subjects affected / exposed	84 / 258 (32.56%)	192 / 534 (35.96%)	
number of deaths (all causes)	219	409	
number of deaths resulting from adverse events	12	35	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon adenoma			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritumoural oedema			

subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour associated fever			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour pain			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Embolism venous			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemic shock			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superior vena cava syndrome			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Death			
subjects affected / exposed	2 / 258 (0.78%)	6 / 534 (1.12%)	
occurrences causally related to treatment / all	1 / 2	2 / 6	
deaths causally related to treatment / all	1 / 2	2 / 6	
Chills			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest discomfort			
subjects affected / exposed	0 / 258 (0.00%)	3 / 534 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	1 / 258 (0.39%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	1 / 258 (0.39%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Non-cardiac chest pain			

subjects affected / exposed	1 / 258 (0.39%)	3 / 534 (0.56%)	
occurrences causally related to treatment / all	1 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	2 / 258 (0.78%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	1 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Hypoxia			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Haemoptysis			
subjects affected / exposed	4 / 258 (1.55%)	10 / 534 (1.87%)	
occurrences causally related to treatment / all	2 / 4	2 / 11	
deaths causally related to treatment / all	0 / 1	0 / 0	
Dyspnoea			
subjects affected / exposed	5 / 258 (1.94%)	8 / 534 (1.50%)	
occurrences causally related to treatment / all	0 / 5	1 / 8	
deaths causally related to treatment / all	0 / 2	0 / 0	
Cough			
subjects affected / exposed	0 / 258 (0.00%)	4 / 534 (0.75%)	
occurrences causally related to treatment / all	0 / 0	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Asthma			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-mediated lung disease			
subjects affected / exposed	0 / 258 (0.00%)	8 / 534 (1.50%)	
occurrences causally related to treatment / all	0 / 0	8 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Interstitial lung disease			
subjects affected / exposed	0 / 258 (0.00%)	7 / 534 (1.31%)	
occurrences causally related to treatment / all	0 / 0	7 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary thrombosis			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary oedema			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary haemorrhage			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary embolism			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax spontaneous			

subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	5 / 258 (1.94%)	9 / 534 (1.69%)	
occurrences causally related to treatment / all	0 / 6	2 / 9	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumonitis			
subjects affected / exposed	0 / 258 (0.00%)	15 / 534 (2.81%)	
occurrences causally related to treatment / all	0 / 0	14 / 15	
deaths causally related to treatment / all	0 / 0	1 / 1	
Wheezing			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheal stenosis			
subjects affected / exposed	0 / 258 (0.00%)	3 / 534 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Respiratory failure			
subjects affected / exposed	3 / 258 (1.16%)	6 / 534 (1.12%)	
occurrences causally related to treatment / all	1 / 3	2 / 6	
deaths causally related to treatment / all	0 / 0	2 / 6	
Psychiatric disorders			
Suicide attempt			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			

subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alanine aminotransferase increased			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutrophil count decreased			
subjects affected / exposed	8 / 258 (3.10%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	10 / 10	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Platelet count decreased			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
White blood cell count decreased			
subjects affected / exposed	4 / 258 (1.55%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	4 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Cerebral radiation injury			

subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clavicle fracture			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Forearm fracture			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament rupture			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Limb injury			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			

subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	1 / 258 (0.39%)	3 / 534 (0.56%)	
occurrences causally related to treatment / all	1 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Acute left ventricular failure			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Acute coronary syndrome			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac tamponade			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiogenic shock			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Atrial fibrillation			

subjects affected / exposed	1 / 258 (0.39%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial ischaemia			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocarditis			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	0 / 258 (0.00%)	5 / 534 (0.94%)	
occurrences causally related to treatment / all	0 / 0	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Nervous system disorders			
Brain oedema			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral artery occlusion			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cerebral infarction			

subjects affected / exposed	0 / 258 (0.00%)	3 / 534 (0.56%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 2	
Epilepsy			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial pressure increased			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			

subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual pathway disorder			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Agranulocytosis			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia			
subjects affected / exposed	5 / 258 (1.94%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	5 / 5	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukopenia			
subjects affected / exposed	6 / 258 (2.33%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	7 / 7	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	21 / 258 (8.14%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	22 / 22	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			

subjects affected / exposed	1 / 258 (0.39%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenitis			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	11 / 258 (4.26%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	12 / 12	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Retinal tear			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 258 (0.00%)	3 / 534 (0.56%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspepsia			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			

subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	1 / 258 (0.39%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			

subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 258 (0.00%)	3 / 534 (0.56%)	
occurrences causally related to treatment / all	0 / 0	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cholecystitis			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune hepatitis			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic function abnormal			

subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	1 / 1	
Drug-induced liver injury			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice cholestatic			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Urinary retention			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute kidney injury			
subjects affected / exposed	1 / 258 (0.39%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			

Immune-mediated adrenal insufficiency			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal insufficiency			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glucocorticoid deficiency			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 258 (0.39%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myositis			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint effusion			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Intervertebral disc protrusion			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone pain			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pathological fracture			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal pain			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			

subjects affected / exposed	1 / 258 (0.39%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media chronic			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	19 / 258 (7.36%)	39 / 534 (7.30%)	
occurrences causally related to treatment / all	12 / 21	6 / 48	
deaths causally related to treatment / all	1 / 2	2 / 6	
Pneumonia haemophilus			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia bacterial			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	2 / 258 (0.78%)	3 / 534 (0.56%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 258 (0.00%)	5 / 534 (0.94%)	
occurrences causally related to treatment / all	0 / 0	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			

subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	0 / 258 (0.00%)	2 / 534 (0.37%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	1 / 258 (0.39%)	0 / 534 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoproteinaemia			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ketoacidosis			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 1 diabetes mellitus			
subjects affected / exposed	0 / 258 (0.00%)	1 / 534 (0.19%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 3 %

Non-serious adverse events	Docetaxel	Tislelizumab	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	246 / 258 (95.35%)	498 / 534 (93.26%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	8 / 258 (3.10%)	21 / 534 (3.93%)	
occurrences (all)	9	25	
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 258 (0.39%)	25 / 534 (4.68%)	
occurrences (all)	1	32	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	2 / 258 (0.78%)	21 / 534 (3.93%)	
occurrences (all)	2	21	
Chest discomfort			
subjects affected / exposed	8 / 258 (3.10%)	19 / 534 (3.56%)	
occurrences (all)	8	19	
Asthenia			
subjects affected / exposed	57 / 258 (22.09%)	76 / 534 (14.23%)	
occurrences (all)	64	78	
Malaise			
subjects affected / exposed	17 / 258 (6.59%)	40 / 534 (7.49%)	
occurrences (all)	28	44	
Fatigue			
subjects affected / exposed	24 / 258 (9.30%)	37 / 534 (6.93%)	
occurrences (all)	31	40	
Pyrexia			
subjects affected / exposed	26 / 258 (10.08%)	62 / 534 (11.61%)	
occurrences (all)	29	72	
Non-cardiac chest pain			
subjects affected / exposed	7 / 258 (2.71%)	22 / 534 (4.12%)	
occurrences (all)	9	29	
Oedema peripheral			
subjects affected / exposed	10 / 258 (3.88%)	15 / 534 (2.81%)	
occurrences (all)	11	15	

Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	40 / 258 (15.50%)	111 / 534 (20.79%)	
occurrences (all)	46	128	
Dyspnoea			
subjects affected / exposed	31 / 258 (12.02%)	62 / 534 (11.61%)	
occurrences (all)	35	64	
Haemoptysis			
subjects affected / exposed	17 / 258 (6.59%)	51 / 534 (9.55%)	
occurrences (all)	18	62	
Productive cough			
subjects affected / exposed	22 / 258 (8.53%)	36 / 534 (6.74%)	
occurrences (all)	22	49	
Psychiatric disorders			
Insomnia			
subjects affected / exposed	26 / 258 (10.08%)	34 / 534 (6.37%)	
occurrences (all)	29	58	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	39 / 258 (15.12%)	112 / 534 (20.97%)	
occurrences (all)	47	183	
Aspartate aminotransferase increased			
subjects affected / exposed	32 / 258 (12.40%)	106 / 534 (19.85%)	
occurrences (all)	38	172	
Bilirubin conjugated increased			
subjects affected / exposed	7 / 258 (2.71%)	17 / 534 (3.18%)	
occurrences (all)	9	25	
Blood alkaline phosphatase increased			
subjects affected / exposed	10 / 258 (3.88%)	39 / 534 (7.30%)	
occurrences (all)	13	53	
Blood bilirubin increased			
subjects affected / exposed	15 / 258 (5.81%)	36 / 534 (6.74%)	
occurrences (all)	23	49	
Blood creatine phosphokinase MB increased			

subjects affected / exposed	1 / 258 (0.39%)	21 / 534 (3.93%)
occurrences (all)	1	34
Blood creatine phosphokinase increased		
subjects affected / exposed	2 / 258 (0.78%)	47 / 534 (8.80%)
occurrences (all)	4	97
Blood creatinine increased		
subjects affected / exposed	17 / 258 (6.59%)	37 / 534 (6.93%)
occurrences (all)	22	58
Blood lactate dehydrogenase increased		
subjects affected / exposed	18 / 258 (6.98%)	38 / 534 (7.12%)
occurrences (all)	23	48
Blood thyroid stimulating hormone increased		
subjects affected / exposed	3 / 258 (1.16%)	32 / 534 (5.99%)
occurrences (all)	3	56
Blood urea increased		
subjects affected / exposed	7 / 258 (2.71%)	26 / 534 (4.87%)
occurrences (all)	7	38
Gamma-glutamyltransferase increased		
subjects affected / exposed	15 / 258 (5.81%)	31 / 534 (5.81%)
occurrences (all)	19	47
Lymphocyte count decreased		
subjects affected / exposed	18 / 258 (6.98%)	35 / 534 (6.55%)
occurrences (all)	37	76
Neutrophil count decreased		
subjects affected / exposed	90 / 258 (34.88%)	17 / 534 (3.18%)
occurrences (all)	168	38
White blood cell count increased		
subjects affected / exposed	11 / 258 (4.26%)	20 / 534 (3.75%)
occurrences (all)	13	30
White blood cell count decreased		
subjects affected / exposed	75 / 258 (29.07%)	21 / 534 (3.93%)
occurrences (all)	133	58
Weight decreased		

subjects affected / exposed occurrences (all)	31 / 258 (12.02%) 32	90 / 534 (16.85%) 101	
Neutrophil count increased subjects affected / exposed occurrences (all)	7 / 258 (2.71%) 9	19 / 534 (3.56%) 23	
Platelet count decreased subjects affected / exposed occurrences (all)	9 / 258 (3.49%) 11	21 / 534 (3.93%) 37	
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	13 / 258 (5.04%) 15	19 / 534 (3.56%) 21	
Headache subjects affected / exposed occurrences (all)	12 / 258 (4.65%) 12	23 / 534 (4.31%) 28	
Hypoaesthesia subjects affected / exposed occurrences (all)	13 / 258 (5.04%) 13	6 / 534 (1.12%) 6	
Peripheral sensory neuropathy subjects affected / exposed occurrences (all)	9 / 258 (3.49%) 10	0 / 534 (0.00%) 0	
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	114 / 258 (44.19%) 169	156 / 534 (29.21%) 269	
Neutropenia subjects affected / exposed occurrences (all)	73 / 258 (28.29%) 185	10 / 534 (1.87%) 24	
Leukopenia subjects affected / exposed occurrences (all)	70 / 258 (27.13%) 169	17 / 534 (3.18%) 38	
Febrile neutropenia subjects affected / exposed occurrences (all)	13 / 258 (5.04%) 13	0 / 534 (0.00%) 0	
Thrombocytopenia			

subjects affected / exposed occurrences (all)	9 / 258 (3.49%) 22	20 / 534 (3.75%) 28	
Eye disorders Cataract subjects affected / exposed occurrences (all)	1 / 258 (0.39%) 1	22 / 534 (4.12%) 23	
Gastrointestinal disorders Stomatitis subjects affected / exposed occurrences (all)	12 / 258 (4.65%) 14	6 / 534 (1.12%) 6	
Nausea subjects affected / exposed occurrences (all)	43 / 258 (16.67%) 55	65 / 534 (12.17%) 73	
Diarrhoea subjects affected / exposed occurrences (all)	35 / 258 (13.57%) 51	41 / 534 (7.68%) 52	
Constipation subjects affected / exposed occurrences (all)	44 / 258 (17.05%) 51	74 / 534 (13.86%) 89	
Abdominal pain upper subjects affected / exposed occurrences (all)	10 / 258 (3.88%) 11	16 / 534 (3.00%) 20	
Abdominal distension subjects affected / exposed occurrences (all)	12 / 258 (4.65%) 14	8 / 534 (1.50%) 8	
Toothache subjects affected / exposed occurrences (all)	6 / 258 (2.33%) 7	20 / 534 (3.75%) 23	
Vomiting subjects affected / exposed occurrences (all)	19 / 258 (7.36%) 23	35 / 534 (6.55%) 44	
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)	7 / 258 (2.71%) 7	38 / 534 (7.12%) 41	
Pruritus			

subjects affected / exposed occurrences (all)	5 / 258 (1.94%) 5	41 / 534 (7.68%) 44	
Alopecia subjects affected / exposed occurrences (all)	127 / 258 (49.22%) 130	7 / 534 (1.31%) 7	
Renal and urinary disorders Proteinuria subjects affected / exposed occurrences (all)	6 / 258 (2.33%) 6	17 / 534 (3.18%) 26	
Endocrine disorders Hyperthyroidism subjects affected / exposed occurrences (all)	0 / 258 (0.00%) 0	23 / 534 (4.31%) 23	
Hypothyroidism subjects affected / exposed occurrences (all)	2 / 258 (0.78%) 2	66 / 534 (12.36%) 82	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	23 / 258 (8.91%) 30	68 / 534 (12.73%) 83	
Back pain subjects affected / exposed occurrences (all)	20 / 258 (7.75%) 21	41 / 534 (7.68%) 47	
Pain in extremity subjects affected / exposed occurrences (all)	17 / 258 (6.59%) 23	29 / 534 (5.43%) 36	
Myalgia subjects affected / exposed occurrences (all)	16 / 258 (6.20%) 19	6 / 534 (1.12%) 6	
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all)	23 / 258 (8.91%) 25	55 / 534 (10.30%) 76	
Pneumonia subjects affected / exposed occurrences (all)	18 / 258 (6.98%) 19	40 / 534 (7.49%) 43	

Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	62 / 258 (24.03%)	88 / 534 (16.48%)	
occurrences (all)	71	95	
Hypocalcaemia			
subjects affected / exposed	21 / 258 (8.14%)	29 / 534 (5.43%)	
occurrences (all)	26	49	
Hyperglycaemia			
subjects affected / exposed	29 / 258 (11.24%)	56 / 534 (10.49%)	
occurrences (all)	37	111	
Hyperuricaemia			
subjects affected / exposed	7 / 258 (2.71%)	24 / 534 (4.49%)	
occurrences (all)	10	52	
Hypoalbuminaemia			
subjects affected / exposed	40 / 258 (15.50%)	76 / 534 (14.23%)	
occurrences (all)	64	141	
Hypoproteinaemia			
subjects affected / exposed	7 / 258 (2.71%)	22 / 534 (4.12%)	
occurrences (all)	8	27	
Hypophosphataemia			
subjects affected / exposed	9 / 258 (3.49%)	11 / 534 (2.06%)	
occurrences (all)	16	25	
Hyponatraemia			
subjects affected / exposed	28 / 258 (10.85%)	53 / 534 (9.93%)	
occurrences (all)	37	85	
Hypokalaemia			
subjects affected / exposed	14 / 258 (5.43%)	51 / 534 (9.55%)	
occurrences (all)	16	83	
Hypochloraemia			
subjects affected / exposed	11 / 258 (4.26%)	19 / 534 (3.56%)	
occurrences (all)	13	29	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
14 February 2018	<p>Amendment 1.0 Key Changes:</p> <ul style="list-style-type: none">• Expanded the study to allow the enrollment of about 160 patients outside of China, including Brazil, Bulgaria, Lithuania, Mexico, New Zealand, Poland, Russia, Slovakia, and Turkey.• OS in PD-L1-positive ($\geq 25\%$ TCs) population were changed to be tested at a significance level of 0.007 as the dual primary endpoint.• Updated the planned timing and number of death events for interim and final analyses of OS.• Removed analysis of PD-L1-positive ($\geq 25\%$ TCs) population from interim analysis.• Revised to cap the PD-L1 negative ($< 25\%$ TCs) population to about 60% of ITT population.• Revised the timing of collection of all immune-mediated adverse events (imAEs) and SAEs related to tislelizumab.• Added ophthalmologic exams.• Added questionnaire EQ-5D-5L.
22 May 2018	<p>Amendment 1.0 Addendum 1 Key Changes:</p> <ul style="list-style-type: none">• Added myocarditis and myositis/rhabdomyolysis as potential imAEs and provided guidelines for their diagnostic tests and management.• Added monitoring of serum creatine kinase and creatine kinase cardiac muscle isoenzyme.
20 July 2018	<p>Amendment 2.0 Key Changes:</p> <ul style="list-style-type: none">• Revised exclusion criteria pertaining to chemotherapy and herbal medicine.• Clarified inclusion/exclusion criteria including lines of prior anticancer therapy, wash out period for prior anticancer chemotherapy, herbal medicine, immunotherapy, and radiation.• Added inclusion criterion of ≥ 12 weeks life expectancy.• Added antibiotics wash-out period of 2 weeks prior to randomization.• Added guidance on the assessment of pulmonary function.
09 March 2020	<p>Amendment 3.0 Key Changes:</p> <ul style="list-style-type: none">• Updated the planned timing and number of death events for interim and final analyses of OS• Added symptom scale of QLQ-LC13 to health-related quality of life (HRQoL) measures in statistical analysis• Clarified the definition of window of baseline tumor assessment in screening period• Added tumor-infiltrating immune cells as exploratory biomarker for efficacy

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported